Fig. 2: Neutralization of Delta and Omicron BA.1 and BA.2 by sera of immunocompromised individuals receiving Ronapreve and/or Evusheld as a pre-exposure prophylaxis.
a, Eight individuals from the Orléans cohort were followed longitudinally, before and after Evusheld administration. Anti-S IgGs were measured using the flow cytometry-based S-Flow assay (top panel). Neutralization of Delta and Omicron BA.1 and BA.2 was measured with the S-Fuse assay (bottom panel). The dotted lines indicate the limit of detection of the assays. Three individuals received first Ronapreve and then Evusheld. b, Anti-S IgG levels in sera of individuals before PrEP (naive; n = 11), treated with Ronapreve (n = 18), treated with Evusheld (n = 11) or treated with both Ronapreve and Evusheld (n = 18). Two-sided Kruskall–Wallis test with Dunn’s multiple comparison correction. Naive versus Ronapreve (P < 0.0001), naive versus Ronapreve+Evusheld (P < 0.0001), Evusheld versus Ronapreve+Evusheld (P = 0.024). c, Sero-neutralization of Delta and Omicron BA.1 and BA.2 in the same individuals as in b. Two-sided Friedman tests with Dunn’s multiple comparison correction were performed to compare the different groups. Ronapreve: Delta versus BA.1 (P ≤ 0.0001), Delta versus BA.2 (P ≤ 0.0081), BA.1 versus BA.2 (P ≤ 0.0081); Evusheld: Delta versus BA.1 (P ≤ 0.0001), BA.1 versus BA.2 (P ≤ 0.031); Evusheld+Ronapreve: Delta versus BA.1 (P ≤ 0.0001), Delta versus BA.2 (P ≤ 0.0081), BA.1 versus BA.2 (P ≤ 0.0081).
